{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT04590326: Phase 1/Phase 2 Interventional Recruiting Ovarian Cancer
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03193190: Phase 1/Phase 2 Interventional Active, not recruiting Pancreatic Adenocarcinoma
(2017)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03817424: Phase 1 Interventional Completed Systemic Lupus Erythematosus
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02459886: Phase 1 Interventional Completed Parkinson's Disease
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03733990: Phase 1/Phase 2 Interventional Completed Cancer
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:insulin sudelidec [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04485052: Phase 1/Phase 2 Interventional Suspended Acute Myeloid Leukemia
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Source:
NCT00523159: Phase 2 Interventional Completed Renal Cell Carcinoma
(2007)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03319628: Phase 1/Phase 2 Interventional Active, not recruiting Platinum Resistant Ovarian Cancer
(2017)
Source URL:
Class:
PROTEIN